Skip to main content
SpringerLink
Log in

Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Sulfasalazine appears to exert its beneficial effect in colitis by releasing 5-aminosalicylic acid in the colon, but its use can be limited by side effects. Ipsalazide and balsalazide are novel sulfasalazine analogs designed to release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract. They have a low oral toxicity following single or repeat administration to mouse, rat, and ferret, and balsalazide is not mutagenic in the Ames test. Ipsalazide and balsalazide are split in rat and man, and the urinary and fecal excretion pattern of the 5-aminosalicylic acid released is similar to that of sulfasalazine; the carrier molecules are absorbed to a lesser extent than the sulfapyridine derived from sulfasalazine. These two analogs deserve therapeutic trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baron JH, Connell AM, Lennard-Jones JE, Avery Jones F: Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1:1094–1096, 1962

    Google Scholar 

  2. Misiewicz JJ, Lennard-Jones JE, Connell AM, Baron JH, Avery Jones F: Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1:185–188, 1965

    Google Scholar 

  3. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, Singleton JW: National cooperative Crohn's disease study: Result of drug treatment. Gastroenterology 77:847–869, 1979

    Google Scholar 

  4. van Hees PAM, van Lier HJJ, van Elteren PM, Driessen WMM, van Hogezand RA, TenVelde GPM, Bakker JH, van Tongeren JHM: Effect of sulphasalazine in patients with active Crohn's disease: A controlled double-blind study. Gut 22:404–409, 1981

    Google Scholar 

  5. Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892–895, 1977

    Google Scholar 

  6. van Hees PAM, Bakker JM, van Tongeren JHM: Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study to determine the active therapeutic moeity of sulphasalazine. Gut 21:632–635, 1980

    Google Scholar 

  7. Klotz U, Maier K, Fischer C, Heinkel K: Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 303:1499–1502, 1980

    Google Scholar 

  8. Birnie GG, McLeod TIF, Watkinson G: Incidence of sulphasalazine-induced male infertility. Gut 22:452–455, 1981

    Google Scholar 

  9. Toovey S, Hudson E, Hendry WF, Levi AJ: Sulphasalazine and male infertility: Reversibility and possible mechanism. Gut 22:445–451, 1981

    Google Scholar 

  10. Das KM, Eastwood MA, McManus JPA, Sircus W: The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut 14:631–641, 1973

    Google Scholar 

  11. van Hees PAM: Clinical and pharmacological aspect of sulphasalazine. PhD thesis, University of Nijmegen, Holland, 1979

    Google Scholar 

  12. Goldman P, Peppercorn MA: Salicylazosulphapyridine in clinical practice. Gastroenterology 65:166–169, 1973

    Google Scholar 

  13. Jewell DP, Truelove SC: Disodium azodisalicylate in ulcerative colitis. Lancet 2:1168–1169, 1981

    Google Scholar 

  14. Willoughby CP, Aronson JK, Agback H, Bodin NO, Andersson E, Truelove SC: Disposition in normal volunteers of sodium azodisalicylate, a potential therapeutic agent in inflammatory bowel disease. Gut 22:A431, 1981

    Google Scholar 

  15. Chan RP: British UK Patent Application GB 2,080,796, 1982

  16. Ames BN, McCann J, Yamasaki E: Methods for detecting carcinogens and mutagens with theSalmonella/mammalian-microsome mutagenicity test. Mutat Res 31:347–364, 1975

    Google Scholar 

  17. van Hees PAM, Tuinte JHM, van Rossum JM, van Tongeren JHM: Influence of intestinal transit time on azoreduction of salicylazosulphapyridine (Salazopyrin). Gut 20:300–304, 1979

    Google Scholar 

  18. Sandberg M, Hansson K-A: Determination of salicylazosulphapyridine in biological materials. Acta Pharm Suec 10:107–110, 1973

    Google Scholar 

  19. Bratton AC, Marshall EK: A new coupling component for sulphanilamide determination. J Biol Chem 128:539–550, 1939

    Google Scholar 

  20. Hansson K-A, Sandberg M: Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine. Acta Pharm Suec 10:87–92, 1973

    Google Scholar 

  21. Hansson K-A: Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine. Acta Pharm Suec 10:153–155, 1973

    Google Scholar 

  22. Pieniaszek HJ, Bates TR: Colorimetric determination of 5-aminosalicylic acid and itsN-acetylated metabolites in urine and faeces. Res Commun Chem Path Pharmacol 12:571–581, 1975

    Google Scholar 

  23. Schroder H, Campbell DES: Absorption, metabolism, and excretion of salicylazosulphapyridine in man. Clin Pharm Ther 13:539–551, 1972

    Google Scholar 

  24. Peppercorn MA, Goldman P: The role of intestinal bacteria in the metabolism of salicylazosulphapyridine. J Pharmacol Exp Ther 181:555–562, 1972

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biorex Laboratories Ltd., London, UK

    Rosalind P. Chan PhD, Derek J. Pope PhD, Andrew P. Gilbert BSc, Paul J. Sacra MD, J. H. Baron DM & John E. Lennard-Jones MD

  2. St. Charles' Hospital, UK

    Rosalind P. Chan PhD, Derek J. Pope PhD, Andrew P. Gilbert BSc, Paul J. Sacra MD, J. H. Baron DM & John E. Lennard-Jones MD

  3. St. Mark's Hospital, City Road, EC1V 2PS, London, UK

    Rosalind P. Chan PhD, Derek J. Pope PhD, Andrew P. Gilbert BSc, Paul J. Sacra MD, J. H. Baron DM & John E. Lennard-Jones MD

Authors
  1. Rosalind P. Chan PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Derek J. Pope PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew P. Gilbert BSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul J. Sacra MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. H. Baron DM
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John E. Lennard-Jones MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chan, R.P., Pope, D.J., Gilbert, A.P. et al. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Digest Dis Sci 28, 609–615 (1983). https://doi.org/10.1007/BF01299921

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01299921

Keywords

Search

Navigation